Company: BDRX
Filing Date: 2025-09-12
Form Type: 424B3
Source: 0001214659-25-013681
Chunk: 2

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-12
Form: 424B3
Chunk 2
---
 forth by specific reference in such a filing.

<div align='center'>SUBMITTED HEREWITH</div>

Attached to the Registrant’s Form 6-K filing
for the month of September 2025, and incorporated by reference herein, is:

| Exhibit No. 
 99.1        |     | Description                                                                                                                                                     
 Press Release, dated September 12, 2025                                                                                                                         |
|:------------|:----|:----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 101.INS     |     | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH     |     | INLINE XBRL Taxonomy Extension Schema Document.                                                                                                                 |
| 101.DEF     |     | INLINE XBRL Taxonomy Extension Calculation Linkbase Document.                                                                                                   |
| 101.CAL     |     | INLINE XBRL Taxonomy Extension Definition Linkbase Document.                                                                                                    |
| 101.LAB     |     | INLINE XBRL Taxonomy Extension Label Linkbase Document.                                                                                                         |
| 101.PRE     |     | INLINE XBRL Taxonomy Extension Presentation Linkbase Document.                                                                                                  |
| 104         |     | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)                                                                        |

<div align='center'>SIGNATURE</div>

Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Date: September 12, 2025 | Biodexa Pharmaceuticals PLC 
 By:                         | /s/ Stephen Stamp                                   |
|:-------------------------|:----------------------------|:----------------------------------------------------|
|                          |                             | Stephen Stamp                                       |
|                          |                             | Chief Executive Officer and Chief Financial Officer |

Exhibit 99.1

September 12, 2025

<div align='center'>Biodexa Pharmaceuticals PLC

(“Biodexa” or the “Company”)

Interim results for the six months ended June 30, 2025</div>

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months ended June 30, 2025 which will also be made available on the Company